Literature DB >> 30914311

A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.

You-Cai Zhu1, Wen-Xian Wang2, Chun-Wei Xu3, Wu Zhuang4, Kai-Qi Du1, Gang Chen5, Tang-Feng Lv6, Yong Song6.   

Abstract

Entities:  

Keywords:  Adenocarcinoma; BRAF; Lung; NGS; Rearrangement

Mesh：

Substances：

Year:  2019        PMID： 30914311     DOI： 10.1016/j.cllc.2019.02.020

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  5 in total

Review 1.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-12

2.  Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report.

Authors:  Yun-Tse Chou; Chien-Chung Lin; Chung-Ta Lee; Dean C Pavlick; Po-Lan Su
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

3.  Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review.

Authors:  Yang Yu; Min Yu; Yanying Li; Xiaojuan Zhou; Tian Tian; Yijia Du; Zegui Tu; Meijuan Huang
Journal:  Front Oncol       Date:  2022-08-19       Impact factor: 5.738

4.  Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor.

Authors:  Jia Luo; Alex Makhnin; Yosef Tobi; Linda Ahn; Sara A Hayes; Afsheen Iqbal; Kenneth Ng; Maria E Arcila; Gregory J Riely; Mark G Kris; Helena A Yu
Journal:  JCO Precis Oncol       Date:  2021-01-11

5.  [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-09-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.